News by community

19.09.2017 | LUDWIG SCIENTISTS DISCOVER COMPLEX AXIS OF IMMUNE SUPPRESSION EXPLOITED BY CANCERS

SEPTEMBER 19, 2017, New York — A Ludwig Cancer Research study has uncovered a new mechanism by which cancer cells evade destruction by the immune system. The paper, led by Camilla Jandus of the Lausanne Branch of the Ludwig Institute for Cancer Research, describes how immune cells known as group 2 innate lymphoid cells (ILC2s) are recruited by leukemic cells to suppress an essential anticancer immune response. The study, which appears in the current issue of Nature Communications, further suggests that the newly discovered immunosuppressive axis likely holds sway in other types of cancer—and that it might be disrupted by therapies already in use to treat other diseases.

Read press release

News by community

06.09.2017 | Anergis Announces Top Line Results From Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT

EPALINGES, Switzerland, September 6th, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today the top-line results from the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.

A total of 421 patients were randomized at 38 European trial centers in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden between September 2016 and January 2017. The trial met its objective to provide conclusive results, with well-balanced treatment groups, very few dropouts, and narrow confidence intervals of the observed treatment effects. The pollen exposure was satisfactory as assessed by the data collected from the pollen traps located close to the trial centers.

Read press release

News by community

04.09.2017 | Ludwig Cancer Research releases its Annual Research Highlights Report 2017

Ludwig Annual Research Highlights Report 2017–

“Behind every scientific discovery is a great story. In our 2017 Research Highlights Report, we share the curiosity, collaboration and mentorship behind Ludwig scientists’ latest discoveries. These include advances in immunotherapy, radiotherapy, understanding cancer’s evolution and more. Enjoy!”

2017 Research Highlights Report

News by community

13.07.2017 | SimplicityBio SA Joins 3.2M Eurostars funded HeartLinc Program

SimplicityBio SA Joins 3.2M Eurostars funded HeartLinc Program led by FIRALIS S.A. to develop lncRNA based IVD test for risk of developing heart failure (HF) after acute myocardial infarction (AMI)

Press release available here

News by community

11.07.2017 | NESTLÉ HEALTH SCIENCE ENTERS THE MICROBIOME DIAGNOSTICS FIELD THROUGH A PARTNERSHIP WITH ENTEROME

• Diagnostic innovations in IBD and Liver Disease in the pipeline
• Positioned to shape the microbiome diagnostics market

Epalinges, Switzerland, 11 July 2017 – Nestlé Health Science and Enterome are jointly creating Microbiome Diagnostics Partners (MDP), which aims to lead the development and commercialization of innovative microbiome-based diagnostics with potential to transform therapeutic approaches across a broad spectrum of challenging health conditions, including inflammatory bowel diseases (IBD) and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.

MDP’s initial focus will be accelerating Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). Current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined Dx tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.

Read press release

News by community

07.07.2017 | Alliance lausannoise pour la recherche en oncologie

L’Université de Lausanne, l’Ecole polytechnique fédérale de Lausanne, le CHUV et Roche ont conclu une alliance pour la recherche et le développement de thérapies oncologiques.

L’Université de Lausanne (UNIL), l’Ecole polytechnique fédérale de Lausanne (EPFL) et le Centre hospitalier universitaire vaudois (CHUV) vont ainsi travailler conjointement avec Roche à la réalisation de projets de recherche, d’étape préclinique, clinique et translationnelle, dans des domaines spécifiques de l’oncologie. Les domaines de recherche identifiés sont : l’oncologie et l’immunothérapie, l’imagerie et la thérapie moléculaire, avec un accent sur le microenvironnement tumoral. L’alliance finance, depuis octobre 2016, six projets trans-institutionnels de recherche préclinique, sélectionnés suite à la revue de nombreuses propositions soumises par des chercheurs des trois institutions.

Communiqué de presse

News by biopôle

06.07.2017 | Nasri Nahas, CEO of Biopôle, interviewed on the « Swiss Entrepreneurs Foundation », the new startup fund of CHF 500 Mio announced by the Federal Councillor Mr. Schneider-Ammann.

Nasri Nahas, CEO of Biopôle, interviewed on the « Swiss Entrepreneurs Foundation », the new startup fund of CHF 500 Mio announced by Mr. Johann Schneider-Ammann, Federal Councillor in charge of Economic Affairs, Education and Research (EAER).

In french:

Vidéo RTS Info – le 19h30:

Interview à 1 mn 40s

https://www.rts.ch/play/tv/19h30/video/cest-un-probleme-bien-helvetique-le-financement-des-start-up?id=8751473

Article Le temps: Un demi-milliard pour les start-up? Un «début»

https://www.letemps.ch/economie/2017/07/06/un-demimilliard-startup-un-debut

News by community

22.06.2017 | NESTLÉ HEALTH SCIENCE AND THE STROKE FOUNDATION (AUSTRALIA) COLLABORATE TO IMPROVE LIFE AFTER STROKE FOR SURVIVORS

Nestlé Health Science and the Australian Stroke Foundation have entered into a partnership designed to improve the nutrition and hydration management of stroke survivors. Stroke is one of the leading causes of dysphagia (swallowing difficulties); it is estimated that 40%1 of survivors have an ongoing need for swallowing support, leaving them vulnerable to dehydration, malnutrition and aspiration pneumonia.

More information

News by biopôle

08.06.2017 | BIOPÔLE ANNOUNCES STARTLAB, TAILOR-MADE INCUBATOR FOR LIFE SCIENCE ENTREPRENEURS

BIOPÔLE ANNOUNCES STARTLAB, TAILOR-MADE INCUBATOR FOR LIFE SCIENCE ENTREPRENEURS

  • Plug and play incubator in brand new building ready Q1 2018
  • Fully equipped laboratories and shared offices to welcome 10-12 startups
  • Pay as you play model reduces risk for entrepreneurs and investors
  • Applications now open for aspiring business creators
  • Leading Swiss life sciences community, home to over 50 companies, 25 institutions and world-leading research groups

 

Lausanne, Switzerland, 8 June 2017 – Biopôle SA, a leading Swiss life sciences park, today announced the creation of StartLab, the first incubator dedicated to life sciences located in the Canton of Vaud.

StartLab will offer 700 m2 of fully equipped laboratories and 300 m2 of shared offices, as a new home for 10-12 startup companies of 35-40 persons in total. It will be part of the new 9,000 m2 building developed by Retraites Populaires, a company specialized in life and occupational pensions.

Biopôle has a clear strategy to be one of the best life sciences hubs in Europe, where industry and academia benefit from a vibrant community of exceptional talents, stimulating collaborations, added value services and an unrivalled quality of life.

More information on: https://startlab.biopole.ch

Press release english
Press release french
Press release german

 

News by community

31.05.2017 | World’s fastest Sepsis Test from Abionic Produces Result in Five Minutes when Tested in patients at London and Zurich Hospitals

World’s fastest Sepsis Test from Abionic Produces Result in Five Minutes when Tested in patients at London and Zurich Hospitals

Press release

News by community

23.05.2017 | ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression

– Trial to provide data on safety, tolerability, pharmacokinetics and efficacy
– ADCT-502 represents ADC Therapeutic’s fourth ADC program in clinical trials
 
Lausanne, Switzerland, May 19, 2017 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that the first patient has been dosed in a Phase I clinical trial to evaluate its antibody drug conjugate (ADC) ADCT-502 in patients with advanced solid tumors with HER2 expression.

Press release in PDF: click here

News by community

09.05.2017 | Nestlé Health Science partners with AliHealth for the launch of Boost in China

NESTLÉ HEALTH SCIENCE PARTNERS WITH ALIHEALTH FOR THE LAUNCH OF BOOST IN CHINA
Beijing, 9 May 2017 – Nestlé Health Science and AliHealth, Alibaba’ flagship medical and health e-commerce platform, are partnering to launch a Boost product portfolio in China. Boost is an innovative range of science-based nutrition targeting the needs of the healthy consumers, focusing on China’s busy urban working population.

More information here

News by community

21.04.2017 | SimplicityBio: 2017 Red Herring Top 100 Europe Award Finalist

SimplicityBio has been selected as a  finalist for the Red Herring’s  Top 100 Europe award , a prestigious list honoring the year’s most promising private technology ventures from the European business region.

More information

 

News by community

03.04.2017 | «Les thérapies cellulaires débuteront cet été»

Oncologie : Lana Kandalaft a la lourde tâche d’amener les traitements innovants contre le cancer au chevet des malades. Le point sur l’avancée des recherches menées par le Département d’oncologie CHUV-UNIL.

Les autorités vaudoises et le CHUV mettent le paquet, on le sait, sur la mise au point de thérapies innovantes contre le cancer. Sous l’égide du professeur George Coukos, chef du Département d’oncologie CHUV-UNIL, la voie choisie est celle de l’immunothérapie, à savoir la stimulation du système immunitaire du patient pour qu’il détruise la tumeur. Le Centre de thérapies expérimentales (CTE) est un maillon central de la chaîne de traitement. C’est lui qui, en établissant des ponts entre recherche et clinique, doit amener les innovations au chevet du patient. A sa tête: Lana Kandalaft, débauchée en 2013 de l’Université de Pennsylvanie.

Plus d’informations

News by community

30.03.2017 | NESTLÉ HEALTH SCIENCE AND CHINESE STROKE ASSOCIATION COLLABORATE TO TACKLE SWALLOWING DIFFICULTY (DYSPHAGIA)

Beijing, March 30, 2017 – Nestlé Health Science (NHSc) and the Chinese Stroke Association (CSA) have entered into a collaboration agreement designed to improve the screening, diagnosis and management of dysphagia (swallowing difficulties) amongst stroke patients. Stroke is one of the most common causes of dysphagia; it is estimated that between 3.4 and 7.4 million patients are suffering from dysphagia in China, leaving them vulnerable to dehydration, malnutrition and aspiration pneumonia.

Press release

News by community

15.03.2017 | Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox®, its blood based colorectal cancer test

LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold in the Swiss German market and Liechtenstein.

More information

News by community

14.03.2017 | TAmiRNA And SimplicityBio Join Forces To Improve MicroRNA Biomarker Development

TAmiRNA and SimplicityBio, a Swiss bioinformatics company specialized in in silico biomarker discovery, signed a partnership agreement. The aim of this partnership is to accelerate TAmiRNA´s biomarker development programs and to offer compelling biomarker development services to clients from academia and biotech industry.

More information

News by community

24.02.2017 | Abionic to open distribution channel in the United Kingdom and Ireland

Epalinges, Switzerland, February 24th, 2017 – Abionic SA, a developer of disrupter nanotechnology based point-of-care diagnostic solutions, announced today having signed an exclusive distribution agreement in the United Kingdom and Ireland with Captium Limited.

More information

News by community

13.02.2017 | Ludwig Lausanne’s Johanna Joyce won a Cancer Research UK Grand Challenge award

Ludwig Cancer Research extends its congratulations to Johanna Joyce, who is part of an international multidisciplinary team that has been named a recipient of the Cancer Research UK Grand Challenge award.

More information

News by community

10.02.2017 | Abionic décroche deux nouvelles reconnaissances : les SEF High Potential & Finance Monthly Game Changers Awards

News by community

09.02.2017 | Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT

  • 421 patients randomized at 38 European trial centers
  • Top-line results expected in Q3, 2017

 

EPALINGES, Switzerland, February 8, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.

More information

News by community

07.02.2017 | SimplicityBio appoints Matthew Hall as CEO to drive growth

SimplicityBio SA, a bioinformatics company leader in biomarker discovery, appoints its Co-founder Matthew Hall Ph.D as Chief Executive Officer (CEO). Matthew brings extensive experience in the biotechnology industry combining scientific knowledge, business acumen and leadership to drive the organization and ensure its continuous growth.

More information

News by community

25.01.2017 | ADC Therapeutics ranks #1 in top 20 VC rounds in Switzerland in 2016 with CHF 104 Million

Vaud ranks #1, attracting 51% of the total Swiss startups funding (nearly CHF 1 billion!) and Biopôle-based biotech startup ADC Therapeutics raised the biggest investment round in 2016 in Switzerland (CHF 104 Million).

Read the latest Swiss Venture Capital Report 2017 for more information

News by community

24.01.2017 | Anergis Appoints Klaus Schollmeier As New Chairman Of The Board Of Directors

EPALINGES, Switzerland, January 24, 2017 – Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.

More information

News by community

10.01.2017 | Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)

WILMINGTON, Del. & KENILWORTH, N.J.–(BUSINESS WIRE)–Jan. 9, 2017– Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

View the full release here

News by community

10.01.2017 | A new director for the IUMSP in 2017

Professor Murielle Bochud, currently responsible for the IUMSP’s Division of chronic diseases (dMC), will be the next Chief of Service, director of the IUMSP.

More information

News by community

09.01.2017 | Abionic Receives CE Mark for Most Rapid Sepsis and Iron Deficiency Point of Care Diagnostics

LAUSANNE, Switzerland–(BUSINESS WIRE)–Abionic SA, a developer of disrupter nanotechnology based point-of-care diagnostic solutions, announced today the receipt of CE Mark (Conformité Européenne) for two novel tests using its easy to use testing platform, abioSCOPE. The CE Mark allows Abionic to commercialize its tests for sepsis risk assessment and management (PSP Test) and iron deficiency throughout the European Union.

More information

News by community

05.01.2017 | Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease

Geneva, Switzerland, January 05, 2017 / B3C newswire / — Xigen, a Swiss Company developing therapeutic peptides for the treatment of inflammatory diseases announces today the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology.

View the full release here

News by community

16.12.2016 | CHMP Recommends Approval of Lilly’s Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib – which if approved would be marketed as Olumiant®. Baricitinib would be indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.

View the full release here

News by community

01.12.2016 | MYMETICS STARTS RESEARCH PROJECT WITH SANOFI FOR INFLUENZA VACCINES

Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics’ proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.

More information

News by community

04.11.2016 | NESTLÉ HEALTH SCIENCE INVESTS IN AIMMUNE THERAPEUTICS, CREATING A STRATEGIC COLLABORATION TO DEVELOP DESENSITIZATION THERAPIES ACROSS MULTIPLE FOOD ALLERGIES

• Strategic Collaboration underscores Nestlé Health Science’s commitment to innovation in the management of food allergies and building a broad portfolio of solutions addressing the medical need of patients
• Aimmune is developing treatments for life-threatening food allergies; lead product AR101 is in Phase III for peanut allergy with US FDA Breakthrough Therapy Designation

Epalinges, Switzerland, 4 November 2016 – Nestlé Health Science announced today that it will make an equity investment of USD 145 million in US-based Aimmune Therapeutics (Nasdaq:AIMT), which corresponds to a 15% stake after completion of the transaction. The parties also entered into a strategic collaboration to accelerate the development of innovative oral immunotherapy biologics designed to desensitize people with food allergies and protect them from the consequences of accidental exposure.

Press Release Nestlé Health Science

News by community

25.10.2016 | TATAA Biocenter and SimplicityBio Announce Complete Solution for Biomarker Discovery, Signature Optimization and Validation

Sweden and Monthey, Switzerland – October 25, 2016:

TATAA Biocenter, Europe’s leading provider of genomic services and the world’s foremost organizer of hands-on training in molecular diagnostics has partnered with SimplicityBio, a leading provider of in silico solutions for multivariate and multimodal analyses to offer complete solutions for biomarker discovery, signature optimization and validation. The partnership offers a complete solution comprising biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation leading to robust and reliable biomarker signatures for diagnostics, prognostics and theranostics. Platforms include microarrays, qPCR, dPCR and NGS and virtually any kind of biomarkers with emphasis on mRNA, microRNA, lncRNA, DNA (SNP, CNV, methylation, cfDNA), protein and circulating tumor cells.

Press release TATAA Biocenter and SimplicityBio

News by biopôle

18.10.2016 | New building at Biopôle to welcome more life science organisations from 2018

New building at Biopôle to welcome more life science organisations from 2018

Retraites Populaires will construct and fund the future building at Biopôle, in Epalinges. The two institutions have signed a contract.

Lausanne, 18 October 2016 -­ As of 2018, a new building at Biopôle, in Epalinges, will meet the increasing demand for laboratory and office space. Retraites Populaires and the management of the life science park have signed a contract, appointing the retirement provision specialist from canton Vaud to construct and fund the future building. In exchange, Biopôle will grant Retraites Populaires a “right of use” (droit de superficie) on the plot of land for the new building.
Construction will begin this month, with completion scheduled for January 2018. The new 9000 m2 building will ultimately house numerous companies, generating between 300 and 500 new jobs in addition to the 1100 people who currently work at Biopôle…

Read full press release (Eng)
Read full press release (Fr)
Read full press release (DE)

News by community

18.10.2016 | ADC Therapeutics Announces Closing of $105 Million Private Financing

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $105 million through a private placement. The financing was oversubscribed and supported by both new and existing investors, including Auven Therapeutics, the Wild Family Office and AstraZeneca.

Refer to the PDF for the full press release.

Media contact: Dr. Chris Martin

News by biopôle

16.09.2016 | 300 chercheurs sous un même toit

A Epalinges, un nouveau laboratoire de recherche réunira chercheurs et cliniciens spécialistes de l’immunothérapie, une technique innovante pour combattre le cancer.

Le CHUV a inauguré jeudi un laboratoire de production cellulaire pour l’immunothérapie sur le site Biopôle d’Epalinges. Cette structure permettra d’offrir des traitements de pointe pour la lutte contre
le cancer, grâce à la fabrication de produits thérapeutiques personnalisés qui ciblent directement les tumeurs.

Lien sur l’article du Temps/en ligne

Lien sur l’article du Temps/pdf

 

News by community

02.09.2016 | NESTLÉ HEALTH SCIENCE EXPANDS ITS DYSPHAGIA OFFERING

Investment in company Phagenesis to address swallowing difficulties experienced by stroke patients

Epalinges, Switzerland, 1 September 2016 – Nestlé Health Science is entering into a staged, milestone-based acquisition of Phagenesis Ltd, a UK-based company developing Phagenyx®, an innovative pharyngeal electrical stimulation device to treat dysphagia (swallowing difficulty). The condition is commonly experienced by post stroke patients, but also the elderly and those undergoing post mechanical ventilation in intensive care units (ICU). Phagenyx® is designed to restore the neurological control of swallowing.

>Press Release Nestlé Health Science

News by community

29.08.2016 | Ludwig Cancer Research releases its Annual Research Highlights Report

Ludwig Annual Research Highlights Report –
Our Annual Research Highlights Report is now available! Here we share life-changing discoveries made by Ludwig scientists and share the personal journeys, fascinations and partnerships behind the science.

2015 Research Highlights Report

News by community

25.08.2016 | Nestlé Health Science Launches MyTubeFeedingKid.com to Support Pediatric Tube-Feeding Journey

Nestlé Health Science today announced the launch of MyTubeFeedingKid.com, a comprehensive online resource dedicated to children with a feeding tube and other unique nutrition needs.

For more information on the press release, click here: https://www.nestlehealthscience.com/newsroom/press-releases/nestle-health-science-launches-mytubefeedingkidcom-to-support-pediatric-tube-feeding-journey

News by biopôle

20.07.2016 | Lausanne: Biopôle se réorganise pour la gagne!

Le parc scientifique dédié aux sciences de la vie de Lausanne fait peau neuve. Trois ans après le renvoi de 2 administrateurs accusés de gestion déloyale, il vient de se doter d’un nouveau conseil d’administration et d’une stratégie de complètement revue, comme nous l’explique Nasri Nahas, directeur général de Biopôle.

Situé au cœur de la Health Valley, il se repositionne comme un écosystème dynamique et proactif orienté davantage vers l’oncologie et ouvert à une plus grande mixité d’acteurs. l’Institut international Ludwig de recherche sur le cancer vient d’ailleurs d’annoncer son installation sur le site, avec un investissement de 274 M€ sur les 30 ans à venir…..

Suite de l’article de Biotech Finances

News by biopôle

11.07.2016 | BIOPOLE ANNOUNCES NEW BOARD OF DIRECTORS AS KEY STEP IN RE-POSITIONING OF LEADING SWISS LIFE SCIENCES COMMUNITY

• New Board and management with clear strategy for benefit of members
• Vibrant life sciences community in Lausanne set for major expansion
• World-class academia and industry focused on oncology, immunology, personalized medicine and nutritional health
• Ludwig Cancer Research to join Biopôle

Lausanne, Switzerland, 11 July 2016 – Biopôle SA, a leading life sciences park located in the Swiss Canton of Vaud, today announced the appointment of a new Board of Directors responsible for its strategic management and future development. The new Board is another key step in the re-positioning of Biopôle in Switzerland and internationally, following the appointment in October 2015 of new CEO Nasri Nahas.

Biopôle has a clear strategy to be one of the best life sciences locations in Europe where industry and academia benefit from a vibrant community of exceptional talents, stimulating collaborations, added value services and an unrivalled quality of life…

> Read full press release (Eng)
> Read full press release (Fr)
> Read full press release (DE)

News by community

09.05.2016 | Novigenix publishes multi-center study of Colox® in Clinical Cancer Research

Novigenix publishes multi-center study of Colox® in Clinical Cancer Research : Data validate blood-based test’s ability to detect colorectal cancer early and reliably.

Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer (CRC).

Press release Novigenix

News by community

09.05.2016 | Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe

Incyte Corporation(Nasdaq:INCY) and ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) today announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations. At the close of the transaction, the companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialize Iclusig® (ponatinib) in Europe and other select countries.

> Press release ARIAD

News by community

05.04.2016 | Mymetics announces successful preclinical results with malaria transmission-blocking vaccine candidate

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines to prevent transmission of human infectious diseases, announced today that the preclinical study with Mymetics’ virosome based formulations for a malaria transmission-blocking vaccine candidate has been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.

> Press release Mymetics

News by community

04.04.2016 | Anergis Closes CHF 5 Million Financing Round Extension to Conduct the ATIBAR Trial

Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT.

> Press release Anergis

News by community

04.09.2015 | ADC Therapeutics lève $ 80 millions

ADC Therapeutics, an oncology drug discovery and development company headquartered in Biopôle (technological parc – Epalinges near Lausanne), today announced that it has raised $80 million through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auven Therapeutics and participation from AstraZeneca.

> Website

News by biopôle

18.06.2015 | Nasri Nahas nommé à la direction de Biopôle S.A.

Le Conseil d’administration de Biopôle SA a nommé Monsieur Nasri Nahas (43 ans) en tant que nouveau directeur du parc vaudois dédié à l’accueil d’entreprises des sciences de la vie. Biologiste et ingénieur de formation, au bénéfice d’une riche expérience de management dans plusieurs entreprises biotech, actif professionnellement depuis 14 ans en Suisse romande, Nasri Nahas entrera en fonction le 1er octobre 2015.

Communiqué de presse

News by biopôle

15.06.2015 | L’Institut Ludwig va s’installer au Biopôle

Un bâtiment dédié à l’oncologie et destiné à accueillir les chercheurs de l’Institut Ludwig, dont l’effectif augmentera, sera construit sur le site du Biopôle. En effet, le Ludwig Cancer Research, a désigné l’Institut Ludwig de Lausanne, installé depuis le début des années 1970 dans la capitale vaudoise, comme site prioritaire pour bénéficier de son généreux soutien à la recherche fondamentale sur le cancer. Cette filiale de la Fondation Ludwig, une parmi douze disséminées à travers le monde, bénéficiera d’une concentration des moyens financiers de la fondation.

Source: 24heures

> Article du 24heures

> Ludwig Cancer Research

> Institut Ludwig de Lausanne

> Communiqué de presse de l’Etat de Vaud

News by biopôle

05.03.2015 | Inauguration de la permanence Mobilité

Le nouveau plan d’affectation cantonal du site « Vennes » (60 entreprises, environ 2’000 employés en 2016) fixe des objectifs ambitieux en terme de mobilité durable. Conscient du défi et de l’enjeu, l’organe de gestion du site – dont font partie Biopôle SA, les communes territoriales, Lausanne Région, des entreprises du site et certains services cantonaux – a décidé de mettre en place des mesures d’incitation à des solutions de mobilité alternatives, dont la principale est l’ouverture d’une permanence mobilité inaugurée le 5 mars 2015 au Biopôle.

> Communiqué de presse

News by biopôle

05.12.2014 | Nouveau financement de CHF 14.5 millions pour Anergis

Anergis, société basée au Biopôle, a obtenu un nouveau financement de CHF 14.5 millions. Félicitations!

> Communiqué de presse

News by biopôle

14.11.2014 | Le Conseil d’administration se renforce

Le Conseil d’administration se renforce avec l’arrivée de M. Maurice Mischler, Syndic et représentant de la Commune d’Epalinges.

> Portrait de M. Mischler

News by biopôle

13.02.2014 | Ariad inaugure ses locaux au Biopôle

Une nouvelle entreprise pharmaceutique s’est installée avec 80 employés sur le site du Biopôle. La société américaine Ariad, spécialisée dans la recherche sur le cancer, a inauguré le 12 février 2014 son siège européen dans le bâtiment Terrasse, en présence de son directeur général et fondateur de l’entreprise, Harvey J. Berger.

> Website

News by biopôle

20.08.2013 | Visite d’une délégation Guangzhou Chine

Le 9 août 2013, Biopôle a eu le plaisir de recevoir une délégation de la ville de Guangzhou en Chine. Un accord de partenariat avait été signé entre Bioisland (Guangzhou) et Biopôle en 2010. Le but de la visite était de développer les échanges entre les deux parcs.

News by biopôle

01.03.2013 | Deux sociétés du Biopôle parmi les 50 start-up helvétiques dans lesquelles investir

Le Biopôle tient à féliciter les start-up Zestagen et Legacy Healthcare de figurer parmi les 50 start-up helvétiques dans lesquelles investir, sélectionnées par le magazine économique Bilan et un jury indépendant.

Zestagen est active dans le développement d’anticorps monoclonaux destinés à soigner des maladies telles que le cancer.

Legacy Healthcare quant à elle conçoit, développe et commercialise des traitements innovants dans des aires thérapeutiques ciblées. Dans le domaine de la dermatologie, leurs efforts portent sur des pathologies du cuir chevelu et de la peau.

> Zestagen

> Legacy Healthcare

News by biopôle

04.02.2013 | ARIAD PHARMACEUTICALS s’installera au Biopôle

Un nouvel acteur actif dans la lutte contre le cancer sur l’arc lémanique, ARIAD Pharmaceuticals s’installera au Biopôle dès 2014.

> Communiqué de presse